spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

High performance range of insulated shipping systems

Laminar Medica


Laminar Medica’s Chilltherm® Global range of high performance insulated shipping systems, from 4 to 1130 litres product volume, are designed to offer optimal thermal protection for pharmaceutical products when exposed to extreme climates from -20°C to +40°C.

These shipping systems are pre-qualified to maintain payload integrity between +2°C and +8°C for transit durations of up to 120 hours. Real live data profiles have been used to give customers confidence that the quality and efficacy of their payloads will not be compromised during even the most demanding external temperatures. Cross hemisphere profile testing makes it ideal for clients making transcontinental shipments.

With only three sizes of cool packs used across the range and a common bill of materials for summer and winter pack outs the impact to warehousing and handling is minimised.

phone 44 (0)14 4282 8664
email enquiries@laminarmedica.co.uk
web www.laminarmedica.com
email Unit 4 Tring Industrial Estate, Icknield Way, Tring, Hertfordshire, HP23 4JX
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Novozymes VELTIS® half-life extension technology used by GlaxoSmithKline in type 2 diabetes drug approved in Europe

Copenhagen, Denmark – 31 March 2014 – Novozymes Biopharma DK A/S, a subsidiary of Novozymes A/S, a world leader in bioinnovation, has announced that its albumin-based VELTIS half-life extension technology is being used by GlaxoSmithKline in the recently authorized Eperzan® (albiglutide) for the treatment of type 2 diabetes in Europe.
More info >>


White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

Industry Events

3rd Annual ClinTech EU

20-21 May 2014, Dublin, Ireland

ClinTech EU provides the opportunity for clinical executives, business system owners and their teams to come together to learn the latest applications of clinical technology to facilitate the operational effectiveness of clinical trials.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement